PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase II drugs for Neuroendocrine Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PT-217’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PT-217 overview
PT-217 is under development for the treatment of small-cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer and gastroenteropancreatic neuroendocrine tumors (GEP-NET). The drug candidate is a bi-specific monoclonal antibody acts by targeting cells expressing DLL3 and leukocyte surface antigen CD47.
Phanes Therapeutics overview
Phanes Therapeutics is a biotech company focused on discovery and development of therapeutics for metabolic complications and various types of cancer. Our extensive experience and deep scientific know-how strongly position us to discover and advance robust therapeutic molecules. Through scientific innovation, we deliver better treatment options for patients. Our mission is to relentlessly seek scientific and technological solutions to improve the lives of patients globally.
For a complete picture of PT-217’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
